A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause
- Registration Number
- NCT06206408
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed.
Researchers want to find other ways to treat hot flashes. Fezolinetant is a medicine to treat hot flashes in women going through menopause. Fezolinetant is an approved medicine in the US. Further studies are needed before it is available in other regions such as Asia.
This study will confirm if fezolintant helps reduce the number of hot flashes in Japanese women going through menopause.
Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. Before the women are assigned a treatment, they will record information about their hot flashes.
Women will either take a lower or higher dose of fezolinetant, or a placebo. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it.
The women will take 2 tablets of the study medicine (lower or higher dose of fezolinetant, or the placebo) once a day for up to 12 weeks. They will either take 1 tablet of fezolinetant (higher or lower dose) and 1 placebo tablet, or they will take 2 placebo tablets. The women will continue to record information about their hot flashes on the electronic device or their smartphone.
During the study, the women will visit the study clinic a few times. At each visit they will be asked if they had any medical problems and will use an electronic device at the clinic to answer questions about how the hot flashes affect their daily life. Other checks will include a medical examination, vital signs (temperature, blood pressure and pulse). Some blood and urine samples will be taken for laboratory tests. At some visits, the women will also have an ECG to check their heart rhythm. Women who have a womb (uterus) will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs.
The last clinic visit will be 3 weeks after the women take their final tablets of the study medicine (1 tablet of lower or higher dose of fezolinetant and 1 placebo tablet, or 2 placebo tablets).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 390
-
Participant confirmed as menopausal per one of the following criteria at the screening visit (visit 1):
- Spontaneous amenorrhea for >/=12 consecutive months;
- Spontaneous amenorrhea for >/=6 months with biochemical criteria of menopause (follicle-stimulating hormone (FSH) > 40 IU/L);
- Having had bilateral oophorectomy >/=6 weeks prior to the screening visit (visit 1) (with or without hysterectomy); or
- Having had hysterectomy without bilateral oophorectomy with the biochemical criteria of menopause (FSH > 40 IU/L).
-
Participant must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and meet some set criteria related to hot flash(es) (HFs) (VMS) prior to randomization.
-
Participant agrees not to participate in another interventional study while participating in the present study.
- Participant has a history of an undiagnosed uterine bleeding within the 6 months prior to the screening visit (visit 1).
- Participant has a current malignant tumor or history (except for a participant who has not received treatment for malignant tumors for at least 5 years before informed consent acquisition and was not considered to have recurrence) of a malignant tumor except for non-metastatic basal cell carcinoma of the skin.
- Participant has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) that could confound interpretation of the study outcome.
- Participant uses a prohibited therapy (hormone therapy, hormone replacement therapy (HRT), hormonal contraceptive, any treatment for menopausal symptoms [prescription medications, over-the-counter, or herbal/Kampo medicines] or strong or moderate cytochrome P450 1A2 (CYP1A2) inhibitors) and is not willing to wash out or discontinue use of such drugs from screening visit (visit 1) through the follow-up visit (visit 6) or it is not medically appropriate to discontinue such drugs for the duration of the study.
- Participant has been randomized/registered in a clinical study with fezolinetant previously or had previous exposure to marketed fezolinetant elsewhere.
- Participant has a present or previous history of participation in this study.
- Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening (visit 1).
- Participant has an unacceptable result from the transvaginal ultrasound (TVU) assessment at screening (i.e., full length of endometrial cavity cannot be visualized or presence of clinically significant abnormal findings).
- Participant has documentation of a clinically significant abnormal Papanicolaou (Pap) test (or equivalent cervical cytology) within the 12 months prior to the screening visit (visit 1) or at screening.
- Participant has active liver disease, jaundice, or elevated liver aminotransferases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST)), elevated total bilirubin (TBL) or direct bilirubin (DBL), elevated international normalized ratio (INR), or elevated alkaline phosphatase (ALP) at screening. A participant with mildly elevated ALT or AST up to < 1.5 × upper limit of normal (ULN) can be enrolled if TBL and DBL are normal. Participant with mildly elevated ALP (up to < 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Participant with Gilbert's syndrome with elevated TBL may be enrolled as long as DBL, hemoglobin and reticulocytes are normal.
- Participant has creatinine > 1.5 × ULN or estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula </=30 mL/min/1.73 m^2 at screening.
- Participant has positive hepatitis serology panel (i.e., positive hepatitis B surface (HBs) antigen and/or positive hepatitis C virus (HCV) antibody) at screening. If HCV antibody test result is equivocal, hepatitis C virus ribonucleic acid (HCV RNA) test at study site is allowed. Participant can be enrolled if that result is normal or not abnormal.
- Participant is not in good general health as determined on the basis of medical history and general physical examination performed at the screening; hematology parameters, biochemistry parameters, pulse rate, blood pressure, electrocardiogram (ECG) outside the reference range for the population studied, or is showing clinically relevant deviations.
- Participant has a history of suicide attempt or suicidal behavior within the 12 months prior to study enrollment or suicidal ideation within the 12 months prior to study enrollment (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale (C-SSRS)), or is at significant risk to commit suicide at day 1 (visit 2).
- Participant is unable or unwilling to complete the study procedures.
- Participant has any condition which makes the participant unsuitable for study participation.
- Participant has a known or suspected hypersensitivity to fezolinetant or any components of the formulation used.
- Participant is the investigator or a member of the study site staff.
- Participant is an employee of Astellas, the study-related contract research organizations (CROs) or site management organization.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Fezolinetant low dose Fezolinetant Participants will receive low dose of fezolinetant and placebo once daily for 12 weeks. Fezolinetant low dose Placebo Participants will receive low dose of fezolinetant and placebo once daily for 12 weeks. Fezolinetant high dose Fezolinetant Participants will receive high dose of fezolinetant and placebo once daily for 12 weeks. Fezolinetant high dose Placebo Participants will receive high dose of fezolinetant and placebo once daily for 12 weeks. Placebo Placebo Participants will receive matching placebo once daily for 12 weeks.
- Primary Outcome Measures
Name Time Method Mean change from baseline in the frequency of mild to severe vasomotor symptoms (VMS) Baseline and Week 8 Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day.
- Secondary Outcome Measures
Name Time Method Percent reduction of >/= 75% in the frequency of moderate to severe VMS from baseline Baseline and up to Week 12 Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of \>/= 75% will be reported.
Mean change from baseline in the frequency of mild to severe VMS Baseline and up to Week 12 Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day.
Percent reduction of >/= 75% in the frequency of mild to severe VMS from baseline Baseline and up to Week 12 Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of \>/= 75% will be reported.
Percent reduction of >/= 50% in the frequency of moderate to severe VMS from baseline Baseline and up to Week 12 Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of \>/= 50% will be reported.
Number of participants with laboratory value abnormalities and/or AEs Up to Week 15 Number of participants with potentially clinically significant laboratory values.
Number of participants with electrocardiogram (ECG) abnormalities and/or AEs Up to Week 12 Number of participants with potentially clinically significant ECG values.
Mean percent reduction in the frequency of moderate to severe VMS from baseline Baseline and up to Week 12 Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Mean percent reduction will be reported.
Percent reduction of 100% in the frequency of mild to severe VMS from baseline Baseline and up to Week 12 Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of 100% will be reported.
Number of participants with Adverse Events (AEs) Up to Week 15 An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.Mean change from baseline in the frequency of moderate to severe VMS Baseline and up to Week 12 Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.
Mean percent reduction in the frequency of mild to severe VMS from baseline Baseline and up to Week 12 Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Mean percent reduction will be reported.
Pharmacokinetics (PK) of fezolinetant in plasma: Concentration Up to Week 12 Concentration will be recorded from the PK plasma samples collected.
Percent reduction of >/= 50% in the frequency of mild to severe VMS from baseline Baseline and up to Week 12 Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of \>/= 50% will be reported.
Percent reduction of 100% in the frequency of moderate to severe VMS from baseline Baseline and up to Week 12 Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of 100% will be reported.
Number of participants with vital sign abnormalities and/or AEs Up to Week 15 Number of participants with potentially clinically significant vital sign values.
Change from baseline in endometrial thickness Baseline and up to Week 12 Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU).
Pharmacokinetics (PK) of metabolite ES259564 in plasma: Concentration Up to Week 12 Concentration will be recorded from the PK plasma samples collected.
Trial Locations
- Locations (64)
Social Medical Corporation Caress Sapporo Caress Memorial Hospital
🇯🇵Sapporo-Shi, Hokkaido, Japan
GyNet Medical Corporation Minamimorimachi Ladies' Clinic
🇯🇵Osaka-shi, Osaka, Japan
Kitahorie Kanade Ladies Clinic
🇯🇵Osaka-shi, Osaka, Japan
Komorebi Ladies Clinic Osaka Honmachi
🇯🇵Osaka-shi, Osaka, Japan
Rikako Ladies Clinic
🇯🇵Osaka-shi, Osaka, Japan
Tennoji Chihiro Women's Clinic
🇯🇵Osaka-shi, Osaka, Japan
Shimizu Ladies Clinic
🇯🇵Sakai-shi, Osaka, Japan
jMOG Medical Corporation Tanabe Ladies' Clinic
🇯🇵Takatsuki-shi, Osaka, Japan
OHARA Clinic
🇯🇵Saitama City, Saitama, Japan
Maruyama Memorial General Hospital
🇯🇵Saitama-shi, Saitama, Japan
Omi Medical Center, Social Medical Corporation Seikoukai
🇯🇵Kusatsu-shi, Shiga, Japan
Omihachiman Community Medical Center
🇯🇵Omihachiman-shi, Shiga, Japan
Sei Women's Clinic
🇯🇵Bunkyo-ku, Tokyo, Japan
Marunouchi no Mori Ladies Clinic
🇯🇵Chiyoda-ku, Tokyo, Japan
Medical Corporation Asbo Tokyo Asbo Clinic
🇯🇵Chuo-ku, Tokyo, Japan
Medical Corp. SEIKOUKAI New Medical Research System Clinic
🇯🇵Hachioji-shi, Tokyo, Japan
Toho Lounge Clinic
🇯🇵Koto-ku, Tokyo, Japan
Machida Municipal Hospital
🇯🇵Machida-shi, Tokyo, Japan
Toranomon Womens Clinic
🇯🇵Minato-ku, Tokyo, Japan
Kichijyoji Ladies Clinic
🇯🇵Musashino-shi, Tokyo, Japan
Shimamura Memorial Hospital
🇯🇵Nerima-ku, Tokyo, Japan
Yukawa Women'S Clinic
🇯🇵Nishitokyo-shi, Tokyo, Japan
Shimodaira Ladies Clinic
🇯🇵Suginami-ku, Tokyo, Japan
Medical Corporation Associa Tamacenter Ladies Clinic
🇯🇵Tama-Shi, Tokyo, Japan
Japan Community Health care Organization Tokuyama Central Hospital
🇯🇵Shunan-shi, Yamaguchi, Japan
NISHIKAWA Women's Health Clinic
🇯🇵Sapporo-shi, Japan
Mori Ladies Clinic
🇯🇵Fukuoka-shi, Fukuoka, Japan
Chita Kosei Hospital
🇯🇵Chita-gun, Aichi, Japan
Juno Vesta Clinic hatta
🇯🇵Matsudo-shi, Chiba, Japan
Fukuoka Mirai Hospital
🇯🇵Fukuoka-shi, Fukuoka, Japan
National Hospital Organization Takasaki General Medical Center
🇯🇵Takasaki-shi, Gunma, Japan
Kotoni Ladies Clinic
🇯🇵Sapporo-shi, Hokkaido, Japan
Miyanomori Ladies' Clinic
🇯🇵Sapporo-Shi, Hokkaido, Japan
Kosumo Clinic
🇯🇵Kako-gun, Hyogo, Japan
Mari Women'S Clinic
🇯🇵Nisinomiya-shi, Hyogo, Japan
JA Toride Medical Center
🇯🇵Toride-city, Ibaraki, Japan
Tsukuba Urocare Clinic
🇯🇵Tsukuba City, Ibaraki, Japan
National Hospital Organization Kanazawa Medical Center
🇯🇵Kanazawa-shi, Ishikawa, Japan
Shonan Kamakura General Hospital
🇯🇵Kamakura-City, Kanagawa, Japan
Kawasakieki Fumi Ladies Clinic
🇯🇵Kawasaki-shi, Kanagawa, Japan
Koukan Clinic
🇯🇵Kawasaki-shi, Kanagawa, Japan
MEITETSU Hospital
🇯🇵Nagoya-shi, Aichi, Japan
Chiba Aoba Municipal Hospital
🇯🇵Chiba-shi, Chiba, Japan
Konan Kosei Hospital
🇯🇵Konan-City, Aichi, Japan
Rakuwakai Otowa Hospital
🇯🇵Kyoto-shi, Kyoto, Japan
Chieko Yukika Lady's Clinic
🇯🇵Sendai-shi, Miyagi, Japan
Daido Clinic
🇯🇵Nagoya-shi, Aichi, Japan
Tsujinaka Hospital Kashiwanoha
🇯🇵Kashiwa-shi, Chiba, Japan
Toyota Kosei Hospital
🇯🇵Toyota-shi, Aichi, Japan
Aiiku Ladies Clinic
🇯🇵Funabashi-shi, Chiba, Japan
Sadamori Ladies Clinic
🇯🇵Hiroshima City, Hiroshima, Japan
Nishiguchi Clinic Fujinka
🇯🇵Fukushima-Shi, Fukushima, Japan
Sato Hospital
🇯🇵Takasaki-shi, Gunma, Japan
Shinkawasaki Kobiki Womens Clinic
🇯🇵Kawasaki-shi, Kanagawa, Japan
Motomachi Ladies Clinic
🇯🇵Yokohama-shi, Kanagawa, Japan
Women's Clinic LUNA Yokohama Motomachi
🇯🇵Yokohama-shi, Kanagawa, Japan
Social Medical Care Corporation Hosei-kai Marunouchi Hospital
🇯🇵Matsumoto-shi, Nagano, Japan
National Hospital Organization Beppu Medical Center
🇯🇵Beppu-shi, Oita, Japan
Miyabi Uro-Gyne Clinic
🇯🇵Okayama-shi, Okayama, Japan
Sawada Lady'S Clinic
🇯🇵Okayama-shi, Okayama, Japan
National Hospital Organization Osaka Minami Medical Center
🇯🇵Kawachinagano-shi, Osaka, Japan
Ninomiya Ladies Clinic
🇯🇵Osaka City, Osaka, Japan
Chayamachi Ladies Clinic
🇯🇵Osaka-shi, Osaka, Japan
Chiharu Clinic
🇯🇵Osaka-shi, Osaka, Japan